Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study (vol 83, pg 15, 2023)

被引：3

作者：

Yu, Evan Y. ^{[1
,2
]}

Piulats, Josep M. ^{[3
]}

Gravis, Gwenaelle ^{[4
]}

Fong, Peter C. C. ^{[5
,6
]}

Todenhoefer, Tilman ^{[7
]}

Laguerre, Brigitte ^{[8
]}

Arranz, Jose A. ^{[9
]}

Oudard, Stephane ^{[10
]}

Massard, Christophe ^{[11
,12
]}

Heinzelbecker, Julia ^{[13
,14
]}

Nordquist, Luke T. ^{[15
]}

Carles, Joan ^{[16
]}

Kolinsky, Michael P. ^{[17
,18
]}

Augustin, Marinela ^{[19
]}

Gurney, Howard ^{[20
]}

Tafreshi, Ali ^{[21
]}

Li, Xin Tong ^{[22
]}

Qiu, Ping ^{[22
]}

Poehlein, Christian H. ^{[22
]}

Schloss, Charles

de Bono, Johann S. ^{[23
,24
]}

机构：

[1] Univ Washington, Seattle, WA USA

[2] Fred Hutchinson Canc Ctr, Seattle, WA USA

[3] Catalan Inst Oncol, Barcelona, Spain

[4] Inst Paoli Calmettes, Marseille, France

[5] Auckland City Hosp, Auckland, New Zealand

[6] Univ Auckland, Auckland, New Zealand

[7] Studienpraxis Urol, Nurtingen, Germany

[8] Ctr Eugene Marquis, Rennes, France

[9] Gen Univ Hosp Gregorio Maranon, Madrid, Spain

[10] Univ Paris, Hop Europeen Georges Pompidou, Paris, France

[11] Gustave Roussy, Canc Campus, Villejuif, France

[12] Paris Saclay Univ, Villejuif, France

[13] Saarland Univ, Med Ctr, Homburg, Germany

[14] Saarland Univ, Fac Med, Homburg, Germany

[15] GU Res Network Urol Canc Ctr, Omaha, NE USA

[16] Vall Hebron Inst Oncol, Barcelona, Spain

[17] Cross Canc Inst, Edmonton, AB, Canada

[18] Univ Alberta, Edmonton, AB, Canada

[19] Paracelsus Med Univ, Nurnberg, Germany

[20] Macquarie Univ, Sydney, Australia

[21] Univ Wollongong, Wollongong, NSW, Australia

[22] Merck & Co Inc, Rahway, NJ USA

[23] Inst Canc Res, London, England

[24] Royal Marsden, London, England

来源：

EUROPEAN UROLOGY | 2023年 / 83卷 / 03期

关键词：

D O I：

10.1016/j.eururo.2022.11.025

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E87 / E87

页数：1

共 50 条

[21] Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
Yu, Evan Y.
Massard, Christophe
Retz, Margitta
Tafreshi, Ali
Carles Galceran, Joan
Hammerer, Peter
Fong, Peter C. C.
Shore, Neal D.
Joshua, Anthony
Linch, Mark David
Gurney, Howard
Romano, Emanuela
Augustin, Marinela
Piulats, Josep M.
Wu, Haiyan
Schloss, Charles
Poehlein, Christian Heinrich
De Bono, Johann S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[22] KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)-naive patients with metastatic castration-resistant prostate cancer (mCRPC)
Todenhoefer, T.
Piulats, J. M.
Ferrario, C.
Linch, M. D.
Stoeckle, M.
Laguerre, B.
Arranz, J. A.
Fong, P. C. C.
Berry, W. R.
Emmenegger, U.
Mourey, L.
Mar, N.
Appleman, L. J.
Joshua, A. M.
Conter, H. J.
Li, X. T.
Schloss, C.
Poehlein, C. H.
De Bono, J. S.
Yu, E. Y.
EUROPEAN UROLOGY, 2022, 81 : S789 - S790
[23] Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update
Mourey, L.
Conter, H. J.
Shore, N.
Berry, W. R.
Fong, P. C.
Piulats, J. M.
Appleman, L. J.
Todenhoefer, T.
Gravis, G.
Laguerre, B.
Gurney, H.
Retz, M.
Romano, E.
de Bono, J. S.
Kam, A. E.
Emmenegger, U.
Wu, H.
Qiu, P.
Schloss, C.
Yu, E. Y.
ANNALS OF ONCOLOGY, 2020, 31 : S516 - S517
[24] Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients
Yu, E.
Piulats, J. M.
Gravis, G.
Fong, P. C. C.
Todenhoefer, T.
Laguerre, B.
Arranz Arija, J. A.
Oudard, S.
Massard, C.
Stoeckle, M.
Nordquist, L. T.
Carles, J.
Kolinsky, M. P.
Augustin, M.
Gurney, H.
Tafreshi, A.
Li, X. T.
Poehlein, C. H.
Schloss, C.
de Bono, J. S.
ANNALS OF ONCOLOGY, 2021, 32 : S652 - S653
[25] Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update
Romano, E.
Sridhar, S. S.
Kolinsky, M. P.
Gravis, G.
Mourey, L.
Piulats, J. M.
Berry, W. R.
Gurney, H.
Retz, M.
Appleman, L. J.
Boegemann, M.
de Bono, J. S.
Joshua, A. M.
Emmenegger, U.
Conter, H. J.
Laguerre, B.
Wu, H.
Qiu, P.
Schloss, C.
Yu, E. Y.
ANNALS OF ONCOLOGY, 2020, 31 : S512 - S513
[26] Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.
Fong, Peter C. C.
Kwiatkowski, Mariusz
Mosca, Alessandra
Valderrama, Begona Perez
Huang, Yi-Hsiu
Zedan, Ahmed H.
Kuc, Kamil
Wiechno, Pawel
Laguerre, Brigitte
Gonzalez-Billalabeitia, Enrique
Osipov, Mikhail
Dede, Didem Sener
Goh, Jeffrey
Daugaard, Gedske
Zhu, Pengfei
Imai, Kentaro
Liu, Yingjie
Arija, Jose Angel Arranz
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 149 - 149
[27] Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.
Yu, Evan Y.
Joshua, Anthony M.
Kramer, Gero
Shore, Neal D.
Hu, Haixia
Poehlein, Christian Heinrich
Schloss, Charles
De Bono, Johann S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS249 - TPS249
[28] Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.
Ferrario, Cristiano
Piulats, Josep M.
Linch, Mark David
Stoeckle, Michael
Laguerre, Brigitte
Arranz, Jose A.
Todenhofer, Tilman
Fong, Peter C. C.
Berry, William R.
Emmenegger, Urban
Mourey, Loic
Mar, Nataliya
Appleman, Leonard Joseph
Joshua, Anthony M.
Conter, Henry Jacob
Li, Xin Tong
Schloss, Charles
Poehlein, Christian Heinrich
De Bono, Johann S.
YuJewish, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[29] Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study
Joshua, A. M.
Gurney, H.
Retz, M.
Tafreshi, A.
Fong, P. C. C.
Shore, N. D.
Romano, E.
Augustin, M.
Piulats, J. M.
Berry, W. R.
Kolinsky, M. P.
Sridhar, S. S.
Conter, H. J.
Todenhoefer, T.
Appleman, L. J.
Wu, H.
Schloss, C.
Poehlein, C. H.
de Bono, J. S.
Yu, E. Y.
ANNALS OF ONCOLOGY, 2020, 31 : S1325 - S1325
[30] Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
Fong, Peter C. C.
Retz, Margitta
Drakaki, Alexandra
Massard, Christophe
Berry, William R.
Romano, Emanuela
De Bono, Johann S.
Feyerabend, Susan
Appleman, Leonard Joseph
Conter, Henry Jacob
Sridhar, Srikala S.
Shore, Neal D.
Linch, Mark David
Joshua, Anthony M.
Gurney, Howard
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →